June 3, 2021
has
a
Amsterdam, the Netherlands –
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced positive two-year results from the Tack Optimized Balloon Angioplasty (TOBA) II below-the-knee (BTK) clinical trial. The data show the Philips Tack Endovascular System (4F), a first-of-its kind dissection repair device, provides a sustained treatment effect and positive impact on quality of life for Peripheral Artery Disease (PAD) and Critical Limb Ischemia (CLI) patients at two years. The data was presented by Co-Principal Investigator George Adams, MD, Interventional Cardiologist at Rex Hospital affiliated with the University of North Carolina at Chapel Hill, at the
Royal Philips
Two-year data from the TOBA II BTK clinical trial demonstrate durability of dissection repair below the knee with the Philips Tack Endovascular System
Two-year data from the TOBA II BTK clinical trial demonstrate durability of dissection repair below the knee with the Philips Tack Endovascular System
June 3, 2021
has
a
Amsterdam, the Netherlands –
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced positive two-year results from the Tack Optimized Balloon Angioplasty (TOBA) II below-the-knee (BTK) clinical trial. The data show the Philips Tack Endovascular System (4F), a first-of-its kind dissection repair device, provides a sustained treatment effect and positive impact on quality of life for Peripheral Artery Disease (PAD) and Critical Limb Ischemia (CLI) patients at two years. The data was presented by Co-Principal Investigator George Adams, MD, Interventional Cardiologist at Rex Hospital affiliated with the Universit
ISCHEMIA Trial Population Reflects Small Slice of US Practice medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
May 06, 2021
Patients with stable ischemic heart disease treated with optimal medical therapy in the ISCHEMIA trial spent more time alive out of the hospital at 2 years when compared with those treated with an invasive strategy, but by 4 years the difference between the two approaches was a wash, according to a new analysis.
When excluding hospitalizations related to the invasive protocol-assigned procedures, there was no statistically significant difference in the number of days spent alive out of hospital (DAOH) between the two treatment strategies at any time point, report investigators.
“DAOH is an important patient-focused metric,” lead investigator Harvey White, DSc (Green Lane Cardiovascular Services/Auckland City Hospital, New Zealand), told TCTMD. “It’s important to measure, as patients value it. Apart from death and a debilitating stroke, patients don’t care that much about endpoints that don’t affect their quality of life. Several studies have shown that